Legal & General Group Plc Takes $7.62 Million Position in Adaptive Biotechnologies Corporation $ADPT

Legal & General Group Plc purchased a new position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 355,336 shares of the company’s stock, valued at approximately $7,622,000. Legal & General Group Plc owned 0.22% of Adaptive Biotechnologies as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of ADPT. Caitong International Asset Management Co. Ltd acquired a new stake in Adaptive Biotechnologies in the fourth quarter valued at $28,000. Allworth Financial LP bought a new stake in shares of Adaptive Biotechnologies in the 2nd quarter valued at about $35,000. EverSource Wealth Advisors LLC grew its position in shares of Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after buying an additional 1,565 shares during the last quarter. KBC Group NV bought a new stake in shares of Adaptive Biotechnologies in the 1st quarter valued at about $45,000. Finally, T. Rowe Price Investment Management Inc. acquired a new stake in shares of Adaptive Biotechnologies in the fourth quarter valued at about $51,000. Institutional investors own 99.17% of the company’s stock.

Analysts Set New Price Targets

ADPT has been the subject of a number of analyst reports. BTIG Research raised their price objective on Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Morgan Stanley upped their target price on Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Thursday, July 30th. JPMorgan Chase & Co. decreased their target price on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Guggenheim raised their price target on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Finally, TD Cowen boosted their price target on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $24.42.

Insider Activity

In related news, Director Peter M. Neupert sold 124,690 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $25.15, for a total value of $3,135,953.50. Following the sale, the director owned 130,625 shares in the company, valued at $3,285,218.75. This represents a 48.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Chad M. Robins sold 321,324 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $25.08, for a total transaction of $8,058,805.92. Following the completion of the sale, the chief executive officer owned 2,180,518 shares in the company, valued at $54,687,391.44. This represents a 12.84% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 2,011,584 shares of company stock valued at $45,765,999. 5.70% of the stock is currently owned by insiders.

Adaptive Biotechnologies Trading Up 1.3%

Shares of Adaptive Biotechnologies stock opened at $24.66 on Thursday. The stock has a market capitalization of $3.94 billion, a PE ratio of -60.15 and a beta of 2.09. Adaptive Biotechnologies Corporation has a 52 week low of $12.00 and a 52 week high of $26.87. The stock has a 50 day moving average price of $23.32 and a two-hundred day moving average price of $17.85. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The firm had revenue of $71.55 million for the quarter, compared to analyst estimates of $65.44 million. During the same period in the previous year, the company earned ($0.17) earnings per share. Adaptive Biotechnologies’s revenue for the quarter was up 21.5% compared to the same quarter last year. As a group, equities analysts anticipate that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current fiscal year.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.